|
Jul 31
|
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
|
|
Jul 31
|
Amicus Therapeutics: Q2 Earnings Snapshot
|
|
Jul 31
|
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
|
|
Jul 25
|
Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion
|
|
Jul 24
|
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
|
|
Jul 21
|
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025
|
|
Jul 18
|
Fabry Disease Treatment Analysis Report 2025 | Market to Reach $3.86 Billion by 2030, Rising Fabry Disease Prevalence and Demand for Targeted Therapies Drive Growth
|
|
Jul 17
|
Starbucks downgraded, Oracle initiated: Wall Street's top analyst calls
|
|
Jul 16
|
Amicus (FOLD) Gets Japan Approval for Pombiliti + Opfolda
|
|
May 21
|
3 High Growth Tech Stocks In The US Market
|
|
May 13
|
Is Amicus Therapeutics (FOLD) the Best Low Priced Biotech Stock to Buy Now?
|
|
Mar 12
|
Amicus Therapeutics, Inc. (FOLD): Among the Stocks Under $10 With High Upside Potential
|
|
Feb 23
|
Why Amicus Therapeutics, Inc. (FOLD) is the Most Oversold Pharma Stock to Buy According to Analysts
|
|
Feb 20
|
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
|
|
Feb 20
|
Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics
|
|
Feb 20
|
Amicus Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
|
|
Feb 20
|
Amicus Therapeutics Inc (FOLD) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
|
Feb 20
|
Q4 2024 Amicus Therapeutics Inc Earnings Call
|
|
Feb 19
|
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates
|
|
Feb 19
|
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
|